INAB IN8bio Inc.
Upcoming Catalysts
| Drug | Stage | Catalyst Date |
|---|---|---|
|
INB-200
Glioblastoma
|
Phase 1
Phase 1
|
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
|
|
INB-100
Allogeneic hematopoietic stem cell transplantation (HSCT)
|
Phase 1
Phase 1
|
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
|
Latest News
-
View Full Article Hide Full Article
- First cohort dosing completed in Phase 1 clinical trials of INB-200 and INB-100
- Data presentations made at ASCO and AACR
- $40M initial public offering (IPO) in August 2021 to fund continuing operations
NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced financial results and operational highlights for the second quarter ended June 30, 2021. In addition, the Company provided an overview of recent corporate developments.
"In the second quarter and subsequent months, we have demonstrated progress in both of our clinical programs," said William Ho, Chief Executive Officer and co-founder of IN8bio. "We successfully completed treatment of the first cohort in the INB-200 Phase 1 trial using our genetically modified gamma-delta T cell candidate in development for treating solid tumors. We also completed dosing of the first cohort of the Phase 1 trial of INB-100, an allogeneic gamma-delta T cell product candidate in development for leukemia patients. We anticipate reporting updates to both programs in the coming months, and given our strengthened cash position from the IPO, we will continue to progress our trials and other pipeline programs."
Successful Initial Public Offering
On August 3, 2021, IN8bio completed its initial public offering, in which it issued and sold 4,000,000 shares of common stock at a public offering price of $10.00 per share. The net proceeds to the Company were approximately $32.6 million, after deducting underwriting discounts, commissions and estimated offering expenses. On September 7, 2021, subsequent to the IPO, there were 18,754,553 shares of common stock outstanding.
Second Quarter Business Highlights & Company Updates
- During the second quarter, IN8bio presented data demonstrating in vitro activity of INB-300, our DeltEx drug-resistant immunotherapy (DRI) CAR-T cells against glioblastoma multiforme (GBM) at the American Association of Cancer Research (AACR) Annual Meeting 2021. Gamma-delta T cells were engineered with a chlorotoxin CAR-T binding domain and a chemotherapy resistance gene, which enhances binding to tumor cells and survival of concomitant dosing with alkylating chemotherapies, such as temozolomide, or TMZ.
- During the second quarter, IN8bio presented data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting from the first cohort of a Phase 1 clinical trial of INB-200 in patients with newly diagnosed GBM. INB-200 was generally well tolerated with no observed infusion reactions, cytokine release syndrome (CRS), neurotoxicity or dose limiting toxicities (DLTs). Enrollment for the second cohort of this trial was initiated. All three treated patients exceeded their expected median progression-free survival based on their respective age and O-6-Methylguanine-DNA Methyltransferase (MGMT) status. The Company expects to report additional data from this Phase 1 trial by the end of 2021.
- In July 2021, IN8bio appointed Emily Fairbairn and Luba Greenwood as two independent members of the Company's Board of Directors. Ms. Fairbairn is currently a principal of Transcend Partners and was co-founder and CEO of Ascend Capital. Ms. Greenwood serves as Managing Partner of Binney Street Capital LLC, a venture capital fund established by the Dana Farber Cancer Institute.
- In August 2021, IN8bio completed dosing of the first cohort of INB-100, a Phase 1 clinical trial of donor-derived allogeneic gamma-delta T cells in leukemia patients undergoing hematopoietic stem cell transplant (HSCT). No severe adverse infusion reactions or DLTs were observed. The first two patients continue in complete remission more than one year after treatment. The Company expects to report initial results from the first cohort in this Phase 1 trial in 2022, with topline results for all cohorts in 2023.
Second Quarter 2021 Financial Highlights
- Cash position: As of June 30, 2021, the Company has cash of $12.0 million, compared to $18.0 million as of December 31, 2020. Subsequent to the end of the second quarter, the Company completed its initial public offering that raised net proceeds of $32.6 million after underwriting discounts, commissions and estimated offering expenses of $7.4 million.
- Research and development (R&D) expense: Research and development expense was $2.1 million for the three months ended June 30, 2021, compared to $1.8 million for the comparable prior year period. The increase in R&D expense was due primarily to third-party costs associated with our clinical programs for INB-200 and increased personnel costs, including non-cash stock-based compensation.
- General and administrative expense: General and administrative expense was $1.0 million for the three months ended June 30, 2021, compared to $1.1 million for the comparable prior year period. The decrease was due primarily to decreased legal and professional fees partially offset by increased personnel costs, including non-cash stock-based compensation.
- Net loss: The Company reported a net loss of $3.1 million and a net loss attributable to common stockholders of $3.8 million, or ($1.00) per basic and diluted common share, for the three months ended June 30, 2021, compared to a net loss of $2.9 million and a net loss attributable to common stockholders of $3.2 million, or ($0.92) per basic and diluted common share, for the comparable prior year period.
IN8BIO, INC.
CONDENSED BALANCE SHEETS
(In thousands, except share and per share data)June 30, 2021 December 31, (unaudited) 2020 Assets (Note 2) Current assets Cash $ 11,999 $ 17,994 Prepaid expenses and other current assets 168 150 Total Current Assets 12,167 18,144 Non-current assets Property and equipment, net 142 186 Deferred offering costs 3,362 2,439 Right of use assets - financing leases 990 — Right of use assets - operating leases 762 — Other non-current assets 141 141 Total Non-Current Assets 5,397 2,766 Total Assets $ 17,564 $ 20,910 Liabilities, Convertible Preferred Stock and Stockholders' Deficit Liabilities Current liabilities Accounts payable $ 462 $ 620 Accrued expenses and other current liabilities 1,485 1,778 Short-term financing lease liability 517 — Short-term operating lease liability 135 — Loan payable, current 174 174 Total Current Liabilities 2,773 2,572 Deferred rent — 17 Long-term financing lease liability 432 — Long-term operating lease liability 698 — Total Liabilities 3,903 2,589 Commitments and Contingencies Convertible preferred stock, Series A, par value $0.0001 per share; 27,564,260 shares authorized at June 30, 2021 and December 31, 2020; 9,993,727 shares, issued and outstanding at June 30, 2021 and December 31, 2020, and a liquidation preference of $39,390 and $37,969 at June 30, 2021 and December 31, 2020, respectively 34,900 34,900 Stockholders' Deficit Common stock, par value $0.0001 per share; 50,700,000 shares authorized at June 30, 2021 and December 31, 2020; 3,764,488 shares issued and outstanding at June 30, 2021 and December 31, 2020, respectively 1 1 Additional paid-in capital 2,211 1,458 Accumulated deficit (23,451 ) (18,038 ) Total Stockholders' Deficit (21,239 ) (16,579 ) Total Liabilities, Convertible Preferred Stock and Stockholders' Deficit $ 17,564 $ 20,910 IN8BIO, INC.
CONDENSED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
(Unaudited)Three Months Ended
June 30,Six Months Ended
June 30,2021 2020 2021 2020 Operating expenses: Research and development $ 2,064 $ 1,784 $ 3,310 $ 2,836 General and administrative 986 1,090 2,103 1,729 Total operating expenses 3,050 2,874 5,413 4,565 Loss from operations (3,050 ) (2,874 ) (5,413 ) (4,565 ) Net loss $ (3,050 ) $ (2,874 ) $ (5,413 ) $ (4,565 ) Net loss attributable to common stockholders (Note 11) $ (3,765 ) $ (3,178 ) $ (6,834 ) $ (5,129 ) Net loss per share attributable to common stockholders – basic and diluted $ (1.00 ) $ (0.92 ) $ (1.82 ) $ (1.52 ) Weighted-average number of shares used in computing net loss per common share, basic and diluted 3,764,488 3,462,182 3,764,488 3,383,774 About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
Certain statements herein concerning the Company's future expectations, plans and prospects, including without limitation, the Company's current expectations regarding the advancement of its product candidates through preclinical studies and clinical trials and the prospects for such candidates and underlying technology, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Company's current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and/or efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company's reliance on third parties, including licensors and clinical research organizations. These risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2021 and other filings and reports that we may file from time to time with the U.S. Securities and Exchange Commission. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
info@IN8bio.comInvestors:
Solebury Trout
David Buck
+ 1 646.378.2927
dbuck@soleburytrout.comMedia:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
+1 212.213.0006 - ext. 364 / 316
rflamm@burnsmc.com / hwong@burnsmc.com
-
View Full Article Hide Full Article
NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced that William Ho, President, Chief Executive Officer and co-founder of IN8bio, will present at the NewYorkBIO Virtual Breakfast Series and the virtual H.C. Wainwright 23rd Annual Global Investment Conference.
Event: NewYorkBIO Virtual Breakfast Series Date: August 31 Presentation: Webinar – Fireside Chat Time: August 31st at 9 am EDT Link: https://bit.ly/3DkM2Rn Event: H.C. Wainwright 23rd Annual Global Investment Conference Date: September 13-14th Presentation: Video presentation Time: Available starting September 13th at 7 am EDT Link: https://bit.ly/3jlRaMQ Webcasts of the presentations can also be accessed through the Events & Presentations section of the Company's website at https://investors.in8bio.com/news-events/events-presentations. The H.C Wainwright presentation will be available for approximately 90 days following the release of the video presentation.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
info@IN8bio.comInvestors:
Solebury Trout
Nicholas Colangelo
+ 1 646.378.2929
ncolangelo@troutgroup.comMedia:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
+1 212.213.0006 - ext. 364 / 316
rflamm@burnsmc.com / hwong@burnsmc.com
-
View Full Article Hide Full Article
The first cohort has completed dosing with IN8bio's donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) observed to date
The first two patients continue to be in complete remission more than one year following INB-100 dosing
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, today announced completion of dosing of the first patient cohort in a Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapeutic in development for patients with leukemia undergoing haploidentical stem cell transplant (HSCT). The three patients comprising the first cohort did not experience any severe adverse infusion reactions or dose limiting toxicities (DLTs) to date. The first two patients are at 14.5 months and 12.2 months, respectively, post-HSCT as of June 30, 2021, and continue to be in complete remission.
"For patients with high-risk leukemia, the availability of HSCT is a path toward a potential cure, but rates of leukemic relapse remain high," said William Ho, Chief Executive Officer and co-founder of IN8bio. "Research by our Chief Scientific Officer, Dr. Lamb, and others has shown that that high numbers of circulating gamma-delta T cells have been correlated with improved survival outcomes in these patients. Our goal with INB-100 is to generate an anti-leukemic effect by supplementing patients' immune systems with allogeneic gamma-delta T cells to reduce relapse and improve overall survival in patients who have undergone an allogeneic HSCT. Although early, we are encouraged by data obtained to date indicating the potential for well-tolerated allogeneic gamma delta T-cell therapies. We look forward to announcing additional data on this program in 2022."
The Phase 1 clinical trial (NCT03533816) is an investigator-sponsored dose escalation trial of INB-100 in patients with leukemias undergoing haploidentical HSCT being conducted at The University of Kansas Cancer Center (KU Cancer Center). Following HSCT, each patient receives a single infusion of IN8bio's donor-derived ex-vivo, expanded, activated gamma delta T-cells. The primary endpoints of this trial are safety and tolerability, and secondary endpoints include rates of GvHD, relapse rate and overall survival. The trial consists of three dose escalation cohorts with topline data expected in 2023.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
For more information about IN8bio and its programs, please visit www.IN8bio.com.
Forward Looking Statements
Certain statements herein concerning the Company's future expectations, plans and prospects, including without limitation, the Company's current expectations regarding the advancement of its product candidates through preclinical studies and clinical trials and the prospects for such candidates and underlying technology, constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Company's current expectations include: scientific, regulatory and technical developments; failure to demonstrate safety, tolerability and efficacy; final and quality controlled verification of data and the related analyses; expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration; and the Company's reliance on third parties, including licensors and clinical research organizations. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstances or otherwise, unless required by applicable law.Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
info@IN8bio.comInvestors:
Solebury Trout
Nicholas Colangelo
+ 1 646.378.2929
ncolangelo@troutgroup.comMedia:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
+1 212.213.0006 - ext. 364 / 316
rflamm@burnsmc.com / hwong@burnsmc.com
-
View Full Article Hide Full Article
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies utilizing its DeltEx platform, announces the appointments of Emily Fairbairn and Luba Greenwood as new members of its Board of Directors.
"Emily and Luba have vast experience as entrepreneurs, executives, board members and investors of companies across multiple therapeutic areas in the biopharmaceutical industry," said Alan S. Roemer, Chairman of IN8bio's Board of Directors. "We welcome them both to our Board of Directors and look forward to their strategic insights and operational guidance as we continue to advance our clinical-stage gamma-delta T-cell programs in solid and liquid tumors. Their experience will be invaluable as we execute on our mission of bringing novel cellular therapies to cancer patients."
Ms. Fairbairn is a highly experienced executive and seasoned investor with decades of experience in financial leadership positions. She is currently a principal of Transcend Partners and was co-founder and CEO of Ascend Capital for nearly 20 years, a San Francisco area based, multi-billion-dollar hedge fund that managed assets for pensions, endowments, public companies and other institutional clients. Prior to Ascend, Ms. Fairbairn conducted equity portfolio construction and financial planning for high-net-worth clients at Merrill Lynch. She currently serves on the funding board of the MIT Sandbox Innovation Fund mentoring aspiring entrepreneurs and is the Chair of the Board at Movano Inc., a medical technology company developing wearable devices that measure key health data including blood glucose levels and blood pressure. She is also a dedicated advocate of funding research for a realizable diagnostic and cure for Lyme+, which affects ~500,000 patients annually in the United States.
Ms. Greenwood is a veteran executive, investor and company builder with deep experience across the life sciences, technology and healthcare sectors. She serves as Managing Partner of Binney Street Capital LLC, a venture capital fund established by the Dana Farber Cancer Institute Venture Fund. Ms. Greenwood co-founded and is currently CEO of LUCA Biologics, Inc., a women's health and microbiome company. Previously, she was Head of Strategic Business Development and Corporate Ventures at Google Life Sciences (now Verily) and Vice President of Global Business Development and Mergers & Acquisitions at F. Hoffmann-La Roche Ltd. where she established and led the East Coast Innovation Hub. She serves on multiple boards, including the Massachusetts Biotechnology Council (MassBio), Kojin, Brooklyn ImmunoTherapeutics, BenchSci and Entrinsic Health. She began her career at Wilmer Cutler Pickering Hale and Dorr as a litigator and regulatory, policy, and intellectual property expert. Ms. Greenwood is a member of the Massachusetts bar.
Ms. Fairbairn will be serving on the nomination and corporate governance committee, while Ms. Greenwood will be serving on the audit and compensation committees. Their terms will both expire at the annual meeting of stockholders to be held in 2022.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product candidates for solid and liquid tumors. Gamma-delta T-cells are a specialized population of T-cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T-cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
For more information about IN8bio and its programs, please visit www.IN8bio.com.
Company Contact:
IN8bio, Inc.
Kate Rochlin, Ph.D.
+1 646.600.6GDT (6438)
info@IN8bio.comInvestors:
Solebury Trout
Nicholas Colangelo
+ 1 646.378.2929
ncolangelo@troutgroup.comMedia:
Burns McClellan, Inc.
Robert Flamm, Ph.D. / Harrison Wong
212-213-0006 ext. 364 / 316
rflamm@burnsmc.com / hwong@burnsmc.com -
View Full Article Hide Full Article
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ:INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies utilizing its DeltEx platform ("IN8bio" or the "Company"), today announced the pricing of its initial public offering of 4,000,000 shares of its common stock at a public offering price of $10.00 per share, for gross proceeds of $40 million, before underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered by IN8bio. IN8bio's common stock is expected to begin trading on The Nasdaq Global Market on July 30, 2021, under the symbol "INAB." The offering is expected to close on August 3, 2021, subject to satisfaction of customary closing conditions. In addition, IN8bio has granted the underwriter a 30-day option to purchase up to an additional 600,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.
B. Riley Securities, Inc. is acting as sole book-running manager for the offering. A registration statement related to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on July 29, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained, when available, from B. Riley Securities, Inc., Attention: Prospectus Department, 1300 North 17th Street, Suite 1300, Arlington Virginia 22209, or by telephone at 703-312-9580, or by email at prospectuses@brileyfin.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio's DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells.
IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types.
Forward Looking Statements
Certain statements herein concerning the Company's future expectations, plans and prospects, including without limitation, the Company's expectations regarding the commencement of trading of its shares, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering, constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Consequently, actual future results may differ materially from the anticipated results expressed in such statements. Specific risks which could cause actual results to differ materially from the Company's current expectations include: the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in biopharmaceutical product development and clinical trials. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" set forth in the Company's filings with the Securities and Exchange Commission. Do not place undue reliance on any forward-looking statements included herein, which speak only as of the date hereof and which the Company is under no obligation to update or revise as a result of any event, circumstance or otherwise, unless required by applicable law.
Investor Contact:
Solebury Trout
Nicholas Colangelo
+ 1 646.378.2929
ncolangelo@troutgroup.comMedia Contact:
Robert Flamm, Ph.D. / Harrison Wong
Burns McClellan, Inc.
212-213-0006 ext. 364 / 316
rflamm@burnsmc.com / hwong@burnsmc.com